{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:33:45Z","timestamp":1784691225262,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.neuropharm.2015.08.019","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T13:12:34Z","timestamp":1439557954000},"page":"85-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions"],"prefix":"10.1016","volume":"106","author":[{"given":"Maximiliano","family":"Rapanelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2117-9321","authenticated-orcid":false,"given":"Christopher","family":"Pittenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molbrainres.2004.02.015","article-title":"Circadian rhythms in behavior and clock gene expressions in the brain of mice lacking histidine decarboxylase","volume":"124","author":"Abe","year":"2004","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2005.11.067","article-title":"Age-dependent measures of anxiety and cognition in male histidine decarboxylase knockout (Hdc-\/-) mice","volume":"1071","author":"Acevedo","year":"2006","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbr.2005.10.016","article-title":"Anxiety and cognition in female histidine decarboxylase knockout (Hdc(-\/-)) mice","volume":"168","author":"Acevedo","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1472-8206.2006.00411.x","article-title":"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice","volume":"20","author":"Akhtar","year":"2006","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"46","key":"10.1016\/j.neuropharm.2015.08.019_bib5","doi-asserted-by":"crossref","first-page":"14423","DOI":"10.1523\/JNEUROSCI.2604-09.2009","article-title":"Orexin\/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models","volume":"29","author":"Anaclet","year":"2009","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2015.08.019_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.smrv.2005.01.001","article-title":"Excessive daytime sleepiness in parkinsonism","volume":"9","author":"Arnulf","year":"2005","journal-title":"Sleep. Med. Rev."},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00213-009-1566-8","article-title":"Effects of the H(3) antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats","volume":"205","author":"Bardgett","year":"2009","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2015.08.019_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuropharm.2010.07.004","article-title":"The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats","volume":"59","author":"Bardgett","year":"2010","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11920-008-0052-z","article-title":"Emerging treatments for Tourette's disorder","volume":"10","author":"Bloch","year":"2008","journal-title":"Curr. Psychiatry Rep."},{"issue":"9","key":"10.1016\/j.neuropharm.2015.08.019_bib10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/CHI.0b013e3181b26e9f","article-title":"Meta-analysis: treatment of attention-deficit\/hyperactivity disorder in children with comorbid tic disorders","volume":"48","author":"Bloch","year":"2009","journal-title":"J.\u00a0Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.08.019_bib11","series-title":"Tourette Syndrome","first-page":"107","article-title":"Clinical course and adult outcome in Tourette syndrome","author":"Bloch","year":"2013"},{"issue":"8","key":"10.1016\/j.neuropharm.2015.08.019_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bcp.2006.10.031","article-title":"Histamine H3 receptor antagonists: from target identification to drug leads","volume":"73","author":"Bonaventure","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-006-0603-0","article-title":"The psychostimulant and rewarding effects of cocaine in histidine decarboxylase knockout mice do not support the hypothesis of an inhibitory function of histamine on reward","volume":"190","author":"Brabant","year":"2007","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbr.2003.11.001","article-title":"Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan","volume":"153","author":"Browman","year":"2004","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-010-1863-2","article-title":"Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists","volume":"210","author":"Burban","year":"2010","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuron.2013.10.052","article-title":"Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice","volume":"81","author":"Castellan Baldan","year":"2014","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10571-011-9730-1","article-title":"Histamine receptor expression, hippocampal plasticity and ammonia in histidine decarboxylase knockout mice","volume":"32","author":"Chepkova","year":"2012","journal-title":"Cell. Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.neuropharm.2015.08.019_bib18","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet. Neurology"},{"issue":"11","key":"10.1016\/j.neuropharm.2015.08.019_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.euroneuro.2013.05.012","article-title":"Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2013","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2015.08.019_bib20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1101\/lm.67603","article-title":"Histidine-decarboxylase knockout mice show deficient nonreinforced episodic object memory, improved negatively reinforced water-maze performance, and increased neo- and ventro-striatal dopamine turnover","volume":"10","author":"Dere","year":"2003","journal-title":"Learn. Mem."},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1460-9568.2004.03546.x","article-title":"Changes in motoric, exploratory and emotional behaviours and neuronal acetylcholine content and 5-HT turnover in histidine decarboxylase-KO mice","volume":"20","author":"Dere","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1756285610390261","article-title":"Treatment strategies for tics in Tourette syndrome","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther. Adv. neurological Disord."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2015.08.019_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.schres.2013.02.030","article-title":"Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia","volume":"146","author":"Egan","year":"2013","journal-title":"Schizophrenia Res."},{"issue":"20","key":"10.1016\/j.neuropharm.2015.08.019_bib24","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa0907006","article-title":"L-histidine decarboxylase and Tourette's syndrome","volume":"362","author":"Ercan-Sencicek","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2015.08.019_bib25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjp.2008.147","article-title":"The histamine H3 receptor: an attractive target for the treatment of cognitive disorders","volume":"154","author":"Esbenshade","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2015.08.019_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.biopsych.2011.09.034","article-title":"Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism","volume":"71","author":"Fernandez","year":"2012","journal-title":"Biol. psychiatry"},{"key":"10.1016\/j.neuropharm.2015.08.019_bib27","series-title":"Tourette's Disorder and Tic Disorders","author":"Fernandez","year":"2015"},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.05.008","article-title":"Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function","volume":"55","author":"Ferrada","year":"2008","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1476-5381.2009.00152.x","article-title":"Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors","volume":"157","author":"Ferrada","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-5793(01)03070-8","article-title":"Histamine deficiency induces tissue-specific down-regulation of histamine H2 receptor expression in histidine decarboxylase knockout mice","volume":"508","author":"Fitzsimons","year":"2001","journal-title":"FEBS Lett."},{"issue":"11","key":"10.1016\/j.neuropharm.2015.08.019_bib31","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/aps.2010.136","article-title":"Ameliorating effect of histamine on impairment of cued fear extinction induced by morphine withdrawal in histidine decarboxylase gene knockout mice","volume":"31","author":"Gong","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neulet.2009.10.079","article-title":"Morphine induces conditioned place preference behavior in histidine decarboxylase knockout mice","volume":"468","author":"Gong","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bbr.2012.04.033","article-title":"Awakening properties of newly discovered highly selective H(3) receptor antagonists in rats","volume":"232","author":"Griebel","year":"2012","journal-title":"Behav. brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1476-5381.2009.00205.x","article-title":"Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-\/- mice","volume":"157","author":"Guo","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2015.08.019_bib35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.neuropharm.2015.08.019_bib36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/schbul\/sbt240","article-title":"A\u00a0randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia","volume":"40","author":"Haig","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00415-011-6171-1","article-title":"Increasing histamine neurotransmission in Gilles de la Tourette syndrome","volume":"259","author":"Hartmann","year":"2012","journal-title":"J.\u00a0Neurology"},{"issue":"7","key":"10.1016\/j.neuropharm.2015.08.019_bib38","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.4088\/JCP.11m07178","article-title":"Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit\/hyperactivity disorder","volume":"73","author":"Herring","year":"2012","journal-title":"J.\u00a0Clin. psychiatry"},{"issue":"12","key":"10.1016\/j.neuropharm.2015.08.019_bib39","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1073\/pnas.0600451103","article-title":"Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice","volume":"103","author":"Huang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2015.08.019_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2015.01.041","article-title":"A\u00a0Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy","volume":"164","author":"Jarskog","year":"2015","journal-title":"Schizophrenia Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1476-5381.2009.00149.x","article-title":"Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases","volume":"157","author":"Jin","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2015.08.019_bib42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/jmedgenet-2013-101637","article-title":"Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families","volume":"50","author":"Karagiannidis","year":"2013","journal-title":"J.\u00a0Med. Genet."},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00213-003-1431-0","article-title":"H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization","volume":"167","author":"Komater","year":"2003","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1046\/j.1471-4159.2002.01189.x","article-title":"Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice","volume":"83","author":"Kubota","year":"2002","journal-title":"J.\u00a0Neurochem."},{"issue":"6","key":"10.1016\/j.neuropharm.2015.08.019_bib45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.sleep.2014.01.021","article-title":"Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review","volume":"15","author":"Leu-Semenescu","year":"2014","journal-title":"Sleep. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2015.08.019_bib46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/smrv.2000.0116","article-title":"Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons","volume":"4","author":"Lin","year":"2000","journal-title":"Sleep. Med. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/jpet.110.170134","article-title":"Histamine H3 receptors and sleep-wake regulation","volume":"336","author":"Lin","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.neuropharm.2015.08.019_bib49","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/hipo.20305","article-title":"Improved learning and memory of contextual fear conditioning and hippocampal CA1 long-term potentiation in histidine decarboxylase knock-out mice","volume":"17","author":"Liu","year":"2007","journal-title":"Hippocampus"},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1734-1140(12)70746-6","article-title":"Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental models","volume":"64","author":"Mahmood","year":"2012","journal-title":"Pharmacol. Rep. P. R."},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0031-9384(92)90157-W","article-title":"Circadian rhythm of histamine release from the hypothalamus of freely moving rats","volume":"51","author":"Mochizuki","year":"1992","journal-title":"Physiology Behav."},{"issue":"17","key":"10.1016\/j.neuropharm.2015.08.019_bib52","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0024-3205(93)90592-Q","article-title":"Involvement of histamine in the control of the waking state","volume":"53","author":"Monti","year":"1993","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.neuropharm.2015.08.019_bib53","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1074\/jbc.M110.161489","article-title":"Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway","volume":"286","author":"Moreno","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"issue":"10","key":"10.1016\/j.neuropharm.2015.08.019_bib54","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1523\/JNEUROSCI.4147-13.2014","article-title":"Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: sigma1-D1-H3 receptor complexes as key targets for reducing cocaine's effects","volume":"34","author":"Moreno","year":"2014","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"issue":"6814","key":"10.1016\/j.neuropharm.2015.08.019_bib55","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35048583","article-title":"High constitutive activity of native H3 receptors regulates histamine neurons in brain","volume":"408","author":"Morisset","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2015.08.019_bib56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.01.021","article-title":"Selective brain region activation by histamine H(3) receptor antagonist\/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression","volume":"70","author":"Munari","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2015.08.019_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-5793(01)02663-1","article-title":"Mice lacking histidine decarboxylase exhibit abnormal mast cells","volume":"502","author":"Ohtsu","year":"2001","journal-title":"FEBS Lett."},{"issue":"7","key":"10.1016\/j.neuropharm.2015.08.019_bib58","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrn3526","article-title":"The histaminergic network in the brain: basic organization and role in disease","volume":"14","author":"Panula","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"17","key":"10.1016\/j.neuropharm.2015.08.019_bib59","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1523\/JNEUROSCI.22-17-07695.2002","article-title":"Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control","volume":"22","author":"Parmentier","year":"2002","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2015.08.019_bib60","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bcp.2007.01.002","article-title":"The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders","volume":"73","author":"Parmentier","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.08.019_bib61","series-title":"Movement Disorders: Genetics and Models","first-page":"748","article-title":"Tourette syndrome","author":"Pittenger","year":"2014"},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0920-9964(94)00034-6","article-title":"Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms","volume":"14","author":"Prell","year":"1995","journal-title":"Schizophrenia Res."},{"issue":"12","key":"10.1016\/j.neuropharm.2015.08.019_bib63","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.euroneuro.2014.10.007","article-title":"Dysregulated intracellular signaling in the striatum in a pathophysiologically grounded model of Tourette syndrome","volume":"24","author":"Rapanelli","year":"2014","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/ejn.12397","article-title":"Periodic properties of the histaminergic system of the mouse brain","volume":"39","author":"Rozov","year":"2014","journal-title":"Eur. J. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2015.08.019_bib65","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1248\/bpb.31.2163","article-title":"Histamine H3 receptor antagonists go to clinics","volume":"31","author":"Sander","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2015.08.019_bib66","series-title":"Tourette Syndrome","first-page":"121","article-title":"The prevalence of Tourette syndrome and its relationship to clinical features","author":"Scahill","year":"2013"},{"issue":"6","key":"10.1016\/j.neuropharm.2015.08.019_bib67","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/mp.2012.69","article-title":"Genome-wide association study of Tourette's syndrome","volume":"18","author":"Scharf","year":"2013","journal-title":"Mol. psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2015.08.019_bib68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1472-8206.1994.tb00789.x","article-title":"Modulation of neurotransmitter release via histamine H3 heteroreceptors","volume":"8","author":"Schlicker","year":"1994","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.08.019_bib69","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neubiorev.2014.03.009","article-title":"Modulation of behavior by the histaminergic system: lessons from H(1)R-and H(2)R-deficient mice","volume":"42","author":"Schneider","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.neuropharm.2015.08.019_bib70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with pitolisant","volume":"163","author":"Schwartz","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2015.08.019_bib71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tins.2014.12.008","article-title":"The human histaminergic system in neuropsychiatric disorders","volume":"38","author":"Shan","year":"2015","journal-title":"Trends Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2015.08.019_bib72","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrneurol.2015.99","article-title":"Interactions of the histamine and hypocretin systems in CNS disorders","volume":"11","author":"Shan","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.neuropharm.2015.08.019_bib73","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/156802608784936728","article-title":"Histamine H3 antagonists as wake-promoting and pro-cognitive agents","volume":"8","author":"Stocking","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2015.08.019_bib74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","article-title":"Clinical and practical considerations in the pharmacologic management of narcolepsy","volume":"16","author":"Thorpy","year":"2015","journal-title":"Sleep. Med."},{"key":"10.1016\/j.neuropharm.2015.08.019_bib75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fnsys.2012.00072","article-title":"Histamine H3 receptor antagonists\/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse","volume":"6","author":"Vohora","year":"2012","journal-title":"Front. Syst. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2015.08.019_bib76","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/11631990-000000000-00000","article-title":"Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder","volume":"26","author":"Weisler","year":"2012","journal-title":"CNS drugs"},{"key":"10.1016\/j.neuropharm.2015.08.019_bib77","series-title":"Neurobiology of Mental Illness","article-title":"Tourette syndrome and tic disorders","author":"Williams","year":"2013"},{"key":"10.1016\/j.neuropharm.2015.08.019_bib78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neulet.2015.03.067","article-title":"Histidine decarboxylase knockout mice, a genetic model of Tourette syndrome, show enhanced stereotypy following stress","volume":"595","author":"Xu","year":"2015","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815300654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815300654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T07:15:26Z","timestamp":1567062926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390815300654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":78,"alternative-id":["S0028390815300654"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.08.019","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}